Mitophagy in cisplatin-induced kidney injury: regulatory mechanisms and therapeutic targets
Cheng Yuan, Jinzhou Jiang, Jinxing Ji, Lihua Ni · 2026
Read Mitophagy in cisplatin-induced kidney injury: regulatory mechanisms and therapeutic targets by Cheng Yuan, Jinzhou Jiang, Jinxing Ji, Lihua Ni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218312.txt.
Description
Cheng Yuan, Jinzhou Jiang, Jinxing Ji, and Lihua Ni review mitophagy in cisplatin-induced kidney injury in a 2026 paper. Cisplatin is a chemotherapy drug, but it frequently damages the kidneys, and the tubular cells that filter blood bear the brunt. Mitophagy, the process that clears mitochondria, sits at the crossroads of the injury pathways, yet its regulatory network in this setting was unsystematized.
The review lists cisplatin's damage mechanisms, including mitochondrial failure, oxidative stress, inflammation, and forms of programmed cell death. It details the two families of mitophagy pathways, those depending on the PINK1 and PARKIN proteins and those that bypass them, and traces how mitophagy talks back to injury processes. A recurring theme is balance: moderate mitophagy protects the kidney by removing damaged mitochondria, while excessive mitophagy deepens the injury. The authors gather preclinical evidence on mitophagy-tuning drugs and discuss what blocks their move into clinical use.
Catalog record
| CREATOR | Cheng Yuan, Jinzhou Jiang, Jinxing Ji, Lihua Ni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 91 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |